(Q48438075)

11 February 2018

title

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. (English)

1 reference

11 February 2018

relapsing-remitting multiple sclerosis

main subject

0 references

0 references

10

1 reference

11 February 2018

author name string

A Paolillo

1

1 reference

11 February 2018

C Pozzilli

2

1 reference

11 February 2018

E Giugni

3

1 reference

11 February 2018

V Tomassini

4

1 reference

11 February 2018

C Gasperini

5

1 reference

11 February 2018

M Fiorelli

6

1 reference

11 February 2018

C Mainero

7

1 reference

11 February 2018

M Horsfield

8

1 reference

11 February 2018

S Galgani

9

1 reference

11 February 2018

C Buttinelli

11

1 reference

11 February 2018

publication date

1 November 2002

1 reference

11 February 2018

European Journal of Neurology

published in

1 reference

11 February 2018

volume

9

1 reference

11 February 2018

issue

6

1 reference

11 February 2018

page(s)

645-655

1 reference

11 February 2018

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Extended observations on MS patients treated with IM interferon-beta1a (Avonex): implications for modern MS trials and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Inflammation and atrophy in multiple sclerosis: MRI associations with disease course

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.2002.00476.X

10.1046/J.1468-1331.2002.00476.X

21 January 2018

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018